

Ellen Heitzer

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6614111/ellen-heitzer-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

109
papers

4,620
citations

33
h-index

67
g-index

119
ext. papers

5,840
ext. citations

7.3
avg, IF

5.88
L-index

#	Paper	IF	Citations
109	Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer.. <i>ESMO Open</i> , 2022 , 7, 100399	6	3
108	Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients. <i>British Journal of Cancer</i> , 2021 ,	8.7	1
107	Longitudinal tumor fraction trajectories predict risk of progression in metastatic HR breast cancer patients undergoing CDK4/6 treatment. <i>Molecular Oncology</i> , 2021 , 15, 2390-2400	7.9	1
106	Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients. <i>Biomolecules</i> , 2021 , 11,	5.9	3
105	Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma. <i>Scientific Reports</i> , 2021 , 11, 12466	4.9	0
104	Expression of the cancer-associated DNA polymerase ϵ P286R in fission yeast leads to translesion synthesis polymerase dependent hypermutation and defective DNA replication. <i>PLoS Genetics</i> , 2021 , 17, e1009526	6	0
103	Ecatenin regulates FOXP2 transcriptional activity via multiple binding sites. <i>FEBS Journal</i> , 2021 , 288, 3261-3284	5.7	3
102	A higher ctDNA fraction decreases survival in regorafenib-treated metastatic colorectal cancer patients. Results from the regorafenib $\bar{\tau}$ liquid biopsy translational biomarker phase II pilot study. <i>International Journal of Cancer</i> , 2021 , 148, 1452-1461	7.5	4
101	Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.. <i>JCO Precision Oncology</i> , 2021 , 5, 1540-1553	3.6	4
100	Tumor-informiert versus Tumor-agnostisch. <i>Trillium-Diagnostik</i> , 2021 , 19, 224-227		
99	Validation of a next-generation sequencing assay for the detection of EGFR mutations in cell-free circulating tumor DNA. <i>Experimental and Molecular Pathology</i> , 2021 , 123, 104685	4.4	0
98	Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trial. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 1758835920987658	5.4	1
97	Detection of Aneuploidy in Cerebrospinal Fluid from Patients with Breast Cancer Can Improve Diagnosis of Leptomeningeal Metastases. <i>Clinical Cancer Research</i> , 2021 , 27, 2798-2806	12.9	2
96	Molecular profiling of soft-tissue sarcomas with FoundationOne Heme identifies potential targets for sarcoma therapy: a single-centre experience. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211029125	5.4	0
95	On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer. <i>Npj Precision Oncology</i> , 2020 , 4, 30	9.8	4
94	Shallow Whole-Genome Sequencing from Plasma Identifies FGFR1 Amplified Breast Cancers and Predicts Overall Survival. <i>Cancers</i> , 2020 , 12,	6.6	8
93	Assessment of Pre-Analytical Sample Handling Conditions for Comprehensive Liquid Biopsy Analysis. <i>Journal of Molecular Diagnostics</i> , 2020 , 22, 1070-1086	5.1	26

92	Technical Evaluation of Commercial Mutation Analysis Platforms and Reference Materials for Liquid Biopsy Profiling. <i>Cancers</i> , 2020 , 12,	6.6	21
91	Functional Classification of Mutations in Acute Myeloid Leukemia. <i>Cancers</i> , 2020 , 12,	6.6	20
90	Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry-based leukemic cell enrichment followed by mutational profiling. <i>American Journal of Hematology</i> , 2020 , 95, 1148	7.1	4
89	Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer. <i>Genome Medicine</i> , 2020 , 12, 20	14.4	16
88	Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors. <i>Genome Medicine</i> , 2020 , 12, 23	14.4	37
87	TP53 mutated AML subclones exhibit engraftment in a humanized bone marrow ossicle mouse model. <i>Annals of Hematology</i> , 2020 , 99, 653-655	3	4
86	Cell-Free DNA and Apoptosis: How Dead Cells Inform About the Living. <i>Trends in Molecular Medicine</i> , 2020 , 26, 519-528	11.5	54
85	Cell-Free DNA Fragmentomics: The New "Omics" on the Block. <i>Clinical Chemistry</i> , 2020 , 66, 1480-1484	5.5	4
84	Novel phenotypes observed in patients with -linked leukaemia/familial thrombocytopenia syndrome and a biallelic risk allele as leukaemogenic cofactor. <i>Journal of Medical Genetics</i> , 2020 , 57, 427-433	5.8	5
83	Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer. <i>ESMO Open</i> , 2020 , 5, e000872	6	9
82	A Multi-Analyte Approach for Improved Sensitivity of Liquid Biopsies in Prostate Cancer. <i>Cancers</i> , 2020 , 12,	6.6	4
81	Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows. <i>Clinical Chemistry</i> , 2020 , 66, 149-160	5.5	51
80	Circulating biomarkers for early detection and clinical management of colorectal cancer. <i>Molecular Aspects of Medicine</i> , 2019 , 69, 107-122	16.7	115
79	State of the Art and Future Direction for the Analysis of Cell-Free Circulating DNA 2019 , 133-188		1
78	Tubuloids derived from human adult kidney and urine for personalized disease modeling. <i>Nature Biotechnology</i> , 2019 , 37, 303-313	44.5	165
77	Human melanoma brain metastases cell line MUG-Mel1, isolated clones and their detailed characterization. <i>Scientific Reports</i> , 2019 , 9, 4096	4.9	4
76	Detection of AML-specific TP53 mutations in bone marrow-derived mesenchymal stromal cells cultured under hypoxia conditions. <i>Annals of Hematology</i> , 2019 , 98, 2019-2020	3	2
75	Untargeted Assessment of Tumor Fractions in Plasma for Monitoring and Prognostication from Metastatic Breast Cancer Patients Undergoing Systemic Treatment. <i>Cancers</i> , 2019 , 11,	6.6	11

74	Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection. <i>Nature Communications</i> , 2019 , 10, 4666	17.4	54
73	Genome-Wide Analysis of the Nucleosome Landscape in Individuals with Coffin-Siris Syndrome. <i>Cytogenetic and Genome Research</i> , 2019 , 159, 1-11	1.9	3
72	Functional Classification of TP53 Mutations in Acute Myeloid Leukemia. <i>Blood</i> , 2019 , 134, 2725-2725	2.2	1
71	Circulating Tumor DNA for Modern Cancer Management. <i>Clinical Chemistry</i> , 2019 ,	5.5	4
70	Current and future perspectives of liquid biopsies in genomics-driven oncology. <i>Nature Reviews Genetics</i> , 2019 , 20, 71-88	30.1	485
69	Detection and Characterization of Circulating Tumor Cells in Patients with Merkel Cell Carcinoma. <i>Clinical Chemistry</i> , 2019 , 65, 462-472	5.5	18
68	Clinical implications of subclonal mutations in acute myeloid leukemia. <i>Haematologica</i> , 2019 , 104, 516-523	23.6	40
67	Single tube liquid biopsy for advanced non-small cell lung cancer. <i>International Journal of Cancer</i> , 2019 , 144, 3127-3137	7.5	35
66	Digital Circulating Tumor Cell Analyses for Prostate Cancer Precision Oncology. <i>Cancer Discovery</i> , 2018 , 8, 269-271	24.4	3
65	Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. <i>International Journal of Cancer</i> , 2018 , 143, 1236-1248	7.5	33
64	Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018 , 93, 23-30	7.1	13
63	G protein-coupled receptor GPR55 promotes colorectal cancer and has opposing effects to cannabinoid receptor 1. <i>International Journal of Cancer</i> , 2018 , 142, 121-132	7.5	36
62	Characterization of the endolysosomal system in human chordoma cell lines: is there a role of lysosomes in chemoresistance of this rare bone tumor?. <i>Histochemistry and Cell Biology</i> , 2018 , 150, 83-92	2.4	9
61	Untargeted profiling of cell-free circulating DNA. <i>Translational Cancer Research</i> , 2018 , 7, S140-S152	0.3	4
60	One size does not fit all: Size-based plasma DNA diagnostics. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	15
59	Somatic mutations characterize preleukemic stem cells in acute myeloid leukemia. <i>Blood</i> , 2017 , 129, 2587-2591	2.2	27
58	Advances in Circulating Tumor DNA Analysis. <i>Advances in Clinical Chemistry</i> , 2017 , 80, 73-153	5.8	20
57	Patient monitoring through liquid biopsies using circulating tumor DNA. <i>International Journal of Cancer</i> , 2017 , 141, 887-896	7.5	35

56	MUG-Mel2, a novel highly pigmented and well characterized NRAS mutated human melanoma cell line. <i>Scientific Reports</i> , 2017 , 7, 2098	4.9	6
55	Potential and Challenges of Liquid Biopsies 2017 , 233-261		
54	miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5. <i>Clinical Cancer Research</i> , 2017 , 23, 5255-5266	12.9	60
53	A novel mutation in ATRX associated with intellectual disability, syndromic features, and osteosarcoma. <i>Pediatric Blood and Cancer</i> , 2017 , 64, e26522	3	15
52	The potential of liquid biopsies for the early detection of cancer. <i>Npj Precision Oncology</i> , 2017 , 1, 36	9.8	82
51	Primary patient-derived lung adenocarcinoma cell culture challenges the association of cancer stem cells with epithelial-to-mesenchymal transition. <i>Scientific Reports</i> , 2017 , 7, 10040	4.9	20
50	Single-Stranded DNA Library Preparation Does Not Preferentially Enrich Circulating Tumor DNA. <i>Clinical Chemistry</i> , 2017 , 63, 1656-1659	5.5	11
49	Expanded molecular profiling of myxofibrosarcoma reveals potentially actionable targets. <i>Modern Pathology</i> , 2017 , 30, 1698-1709	9.8	14
48	Genetic profiling of putative breast cancer stem cells from malignant pleural effusions. <i>PLoS ONE</i> , 2017 , 12, e0175223	3.7	5
47	Characterisation and treatment of patients with castration-resistant metastatic prostate cancer (mCRPC) developing neuroendocrine clonal divergence (NCD): A case series.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16520-e16520	2.2	
46	Inferring expressed genes by whole-genome sequencing of plasma DNA. <i>Nature Genetics</i> , 2016 , 48, 1273-1283	38.3	171
45	Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer. <i>Nature Communications</i> , 2016 , 7, 12008	17.4	98
44	Neueste technologische Entwicklungen für die Analyse von zirkulierender Tumor-DNA. <i>Medizinische Genetik</i> , 2016 , 28, 234-244	0.5	
43	Establishment of clival chordoma cell line MUG-CC1 and lymphoblastoid cells as a model for potential new treatment strategies. <i>Scientific Reports</i> , 2016 , 6, 24195	4.9	10
42	mFast-SeqS as a Monitoring and Pre-screening Tool for Tumor-Specific Aneuploidy in Plasma DNA. <i>Advances in Experimental Medicine and Biology</i> , 2016 , 924, 147-155	3.6	13
41	Academia Meets Industry. <i>Advances in Experimental Medicine and Biology</i> , 2016 , 924, 201-215	3.6	
40	Ein vielversprechendes Werkzeug. <i>Wiener Klinisches Magazin: Beilage Zur Wiener Klinischen Wochenschrift</i> , 2016 , 19, 36-43	0	
39	Co-occurrence of MYC amplification and TP53 mutations in human cancer. <i>Nature Genetics</i> , 2016 , 48, 104-6	36.3	33

38	Non-invasive detection of genome-wide somatic copy number alterations by liquid biopsies. <i>Molecular Oncology</i> , 2016 , 10, 494-502	7.9	54
37	Detection of Circulating Tumor DNA in the Blood of Cancer Patients: An Important Tool in Cancer Chemoprevention. <i>Methods in Molecular Biology</i> , 2016 , 1379, 45-68	1.4	15
36	Exploring chromosomal abnormalities and genetic changes in uterine smooth muscle tumors. <i>Modern Pathology</i> , 2016 , 29, 1262-77	9.8	20
35	POLE mutations in families predisposed to cutaneous melanoma. <i>Familial Cancer</i> , 2015 , 14, 621-8	3	38
34	Rapid Identification of Plasma DNA Samples with Increased ctDNA Levels by a Modified FAST-SeqS Approach. <i>Clinical Chemistry</i> , 2015 , 61, 838-49	5.5	76
33	Clinical utility of circulating tumor DNA in human cancers. <i>Memo - Magazine of European Medical Oncology</i> , 2015 , 8, 222-226	0.3	0
32	Preexisting TP53 mutation in therapy-related acute myeloid leukemia. <i>Annals of Hematology</i> , 2015 , 94, 527-9	3	24
31	Circulating tumor DNA as a liquid biopsy for cancer. <i>Clinical Chemistry</i> , 2015 , 61, 112-23	5.5	531
30	The dynamic range of circulating tumor DNA in metastatic breast cancer. <i>Breast Cancer Research</i> , 2014 , 16, 421	8.3	93
29	Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X. <i>Nature Communications</i> , 2014 , 5, 5191	17.4	47
28	Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1. <i>Modern Pathology</i> , 2014 , 27, 906-15	9.8	18
27	The BRAF V600K mutation is more frequent than the BRAF V600E mutation in melanoma in situ of lentigo maligna type. <i>Journal of Investigative Dermatology</i> , 2014 , 134, 548-550	4.3	20
26	Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. <i>PLoS Genetics</i> , 2014 , 10, e1004271	6	132
25	Hematogenous dissemination of glioblastoma multiforme. <i>Science Translational Medicine</i> , 2014 , 6, 247ra104	10.4	193
24	Replicative DNA polymerase mutations in cancer. <i>Current Opinion in Genetics and Development</i> , 2014 , 24, 107-13	4.9	78
23	Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. <i>Genome Medicine</i> , 2013 , 5, 30	14.4	246
22	Genetic and epigenetic analysis of putative breast cancer stem cell models. <i>BMC Cancer</i> , 2013 , 13, 358	4.8	22
21	Neuropathic cancer pain: prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative-Computerised Symptom Assessment study. <i>Palliative Medicine</i> , 2013 , 27, 714-21	5.5	87

20	Circulating tumor cells and DNA as liquid biopsies. <i>Genome Medicine</i> , 2013 , 5, 73	14.4	99
19	Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. <i>International Journal of Cancer</i> , 2013 , 133, 346-56	7.5	135
18	Depressed patients with incurable cancer: which depressive symptoms do they experience?. <i>Palliative and Supportive Care</i> , 2013 , 11, 491-501	2.5	25
17	Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. <i>Cancer Research</i> , 2013 , 73, 2965-75	10.1	442
16	Depressed patients with incurable cancer: Which depressive symptoms do they experience?ERRATUM. <i>Palliative and Supportive Care</i> , 2013 , 11, 535-535	2.5	
15	Interviews with patients with advanced cancer--another step towards an international cancer pain classification system. <i>Supportive Care in Cancer</i> , 2012 , 20, 2491-500	3.9	8
14	Computer-based symptom assessment is feasible in patients with advanced cancer: results from an international multicenter study, the EPCRC-CSA. <i>Journal of Pain and Symptom Management</i> , 2012 , 44, 639-54	4.8	45
13	Infrequent p53 gene mutation but UV gradient-like p53 protein positivity in keloids. <i>Experimental Dermatology</i> , 2012 , 21, 277-80	4	4
12	IL-7, IL-18, MCP-1, MIP1- β and OPG as biomarkers for pain treatment response in patients with cancer. <i>Pain Physician</i> , 2012 , 15, 499-510	1.8	7
11	Extra phenotypic features in a girl with Miller syndrome. <i>Clinical Dysmorphology</i> , 2011 , 20, 66-72	0.9	5
10	PTCH promoter methylation at low level in sporadic basal cell carcinoma analysed by three different approaches. <i>Experimental Dermatology</i> , 2010 , 19, 926-8	4	17
9	Rapid and reliable detection of LINE-1 hypomethylation using high-resolution melting analysis. <i>Clinical Biochemistry</i> , 2010 , 43, 1443-8	3.5	19
8	Polyclonality of multiple sporadic basal cell carcinomas. <i>Journal of Investigative Dermatology</i> , 2009 , 129, 1586-9	4.3	5
7	High quality assessment of DNA methylation in archival tissues from colorectal cancer patients using quantitative high-resolution melting analysis. <i>Journal of Molecular Diagnostics</i> , 2009 , 11, 102-8	5.1	49
6	Nonmonoclonal PTCH gene mutations in psoralen plus UVA-associated basal cell carcinomas. <i>Journal of Investigative Dermatology</i> , 2008 , 128, 746-9	4.3	3
5	p14ARF hypermethylation is common but INK4a-ARF locus or p53 mutations are rare in Merkel cell carcinoma. <i>Journal of Investigative Dermatology</i> , 2008 , 128, 1788-96	4.3	47
4	UV fingerprints predominate in the PTCH mutation spectra of basal cell carcinomas independent of clinical phenotype. <i>Journal of Investigative Dermatology</i> , 2007 , 127, 2872-81	4.3	26
3	T1799A BRAF mutation is common in PUVA lentiginos. <i>Journal of Investigative Dermatology</i> , 2006 , 126, 1915-7	4.3	13

2	Inferring expressed genes by whole-genome sequencing of plasma DNA	3
1	Inference of tumor cell-specific transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection of cancer	3